The DUS3L Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the DUS3L gene in the human NCI-H1975 non-small cell lung adenocarcinoma cell line. This product provides a heterogeneous pool of edited cells, each carrying gene-specific modifications introduced by the CRISPR/Cas9 system, thereby enabling loss-of-function studies in a physiologically relevant lung cancer background without clonal selection. The polyclonal format preserves the inherent biological variability of the knockout population, making it suitable for pooled functional screens, pathway analysis, and drug-response profiling where population-level effects are informative.
The host cell line, NCI-H1975, is a well-characterized model of human non-small cell lung adenocarcinoma derived from a female patient. This line harbors activating mutations in the epidermal growth factor receptor (EGFR) gene??specifically the L858R point mutation in exon 21 and the T790M gatekeeper mutation in exon 20??which confer constitutive kinase activity and resistance to first-generation tyrosine kinase inhibitors. These oncogenic lesions drive persistent activation of downstream mitogenic cascades, including the RAS?CRAF?CMEK?CERK axis, making NCI-H1975 cells a critical system for studying EGFR-dependent signaling and therapeutic vulnerabilities in lung cancer.
DUS3L encodes a dual-specificity phosphatase that is predicted to dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues on mitogen-activated protein kinases (MAPKs). In the MAPK/ERK pathway, DUS3L likely functions downstream of receptor tyrosine kinase signaling, including EGFR, and acts as a negative feedback regulator by dephosphorylating ERK1/2, JNK, and p38. Upstream regulators such as oncogenic RAS and EGFR-mediated signals promote the activation of the kinase cascade comprising RAF, MEK1/2, and ERK1/2, while DUS3L counteracts this by directly dephosphorylating activated ERK1/2, thereby attenuating signal amplitude and duration. DUS3L also interacts with other tyrosine-phosphorylated substrates and may modulate parallel MAPK branches, positioning it as a key rheostat within the broader signaling network.
In the NCI-H1975 background, knockout of DUS3L is expected to relieve this negative regulation, leading to sustained or elevated phosphorylation of ERK1/2 and other MAPK effectors. This hyperactivation can amplify proliferative and survival signals downstream of the constitutively active EGFR mutants, potentially mimicking or exacerbating oncogenic signaling states observed in aggressive adenocarcinoma. Consequently, the DUS3L knockout model facilitates exploration of how phosphatases constrain oncogenic kinase signaling, how their loss contributes to pathway addiction, and how compensation or rewiring occurs in the context of EGFR-driven lung cancer. The model is especially relevant for dissecting mechanisms of resistance to EGFR inhibitors, where MAPK pathway resurgence often plays a central role.
Researchers can employ these polyclonal knockout cells in a variety of assays to probe MAPK signaling dynamics and therapeutic responses. Common applications include western blotting for phospho-ERK1/2 and other pathway markers, cell proliferation and viability assays, phospho-signaling multiplex analyses, and drug sensitivity screens against EGFR tyrosine kinase inhibitors or MEK inhibitors. The cells are also amenable to RT-qPCR profiling of MAPK target genes and functional rescue experiments. By integrating this knockout tool into comparative studies with parental or mock-edited controls, investigators can delineate DUS3L-dependent regulatory nodes and their impact on lung adenocarcinoma biology. For additional information, support, or bulk ordering, please contact Ascent Research.
